Doctor, Patient Adoption of PGx Testing Increases in PBM-Initiated Programs, Medco Reports at ASHG | GenomeWeb

Originally published Nov. 9.

By Turna Ray

Education and no cost concerns increase the likelihood that doctors and patients will consent to pharmacogenetic testing for warfarin and tamoxifen, according to a two-year study conducted by the Medco Research Institute.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.